PLRX Stock Analysis: Buy, Sell, or Hold?
PLRX - Pliant Therapeutics, Inc. Common Stock
$1.35
0.03 (2.27%)
▲
5d:
+9.76%
30d:
+4.65%
90d:
+10.66%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
PLRX is down 4.3% this week, but smart money is accumulating calls. Top strike: $1.5 2026-04-17 with 2,135 OI. Call ratio: 100% View Scanner →
Strength: 7.2/10
Get Alerted When PLRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PLRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PLRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PLRX is currently trading at $1.35, which is considered fair relative to its 30-day fair value range of $1.24 to $1.34.
Technical Outlook: Technically, PLRX is in a downtrend. The price is approaching resistance at $1.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.67 (+97.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLRX is in a downtrend. The price is approaching resistance at $1.38. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.67 (+97.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.24 -
$1.34
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 97.5% below Wall St target ($2.67)
Fair Price Analysis
30-Day Fair Range
$1.24 -
$1.34
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.14
Resistance Level
$1.38
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.11
Wall Street Target
$2.67
(+97.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 02, 2026 6:29 PM ET
Data refreshes hourly during market hours. Next update: 7:29 PM
Data refreshes hourly during market hours. Next update: 7:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Bernard Coulie
SELL
89375 shares
2026-01-20
Minnie Kuo
SELL
6917 shares
2026-01-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 61 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 61 BUY |
